Antifibrinolytics in Cardiac Surgery: What Is the Best Practice in 2022?
- 13.10.2022
- Blood Management (KA Tanaka, Section Editor)
Erschienen in:
- Verfasst von
- Erik R. Strauss
- Monica Taneja
- Richard Booth
- Susan Sankova
- Megan G. Anders
- Erschienen in
- Current Anesthesiology Reports | Ausgabe 4/2022
Abstract
Purpose of Review
This review describes the latest information related to the administration of lysine analogues during cardiac surgery. An awareness of appropriate antifibrinolytic administration will maximize benefit for blood conservation efforts and possibly decrease morbidity and mortality.
Recent Findings
Recent pharmacodynamic assessments for antifibrinolytics are more sensitive. Research suggests that lower dose regimens may not provide maximal inhibition of fibrinolysis but may be equally effective in decreasing transfusion of blood products. Effective lower dose regimens may decrease the incidence of seizures and possibly morbidity and mortality.
Summary
The lysine analogues are a key addition to blood conservation efforts in cardiac surgery. Finding an optimized dosing regimen is complex and may include factors such as total dosage and timing of administration. Understanding of the pharmacokinetics and pharmacodynamics of these drugs will help perioperative physicians evaluate their own practice and improve their own regimens.
Anzeige
- Titel
- Antifibrinolytics in Cardiac Surgery: What Is the Best Practice in 2022?
- Verfasst von
-
Erik R. Strauss
Monica Taneja
Richard Booth
Susan Sankova
Megan G. Anders
- Publikationsdatum
- 13.10.2022
- Verlag
- Springer US
- Erschienen in
-
Current Anesthesiology Reports / Ausgabe 4/2022
Elektronische ISSN: 2167-6275 - DOI
- https://doi.org/10.1007/s40140-022-00538-w
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
